Date and Time: 8th May 2014, 10.00 – 16.00

Minutes: Final

Guideline Development Group Meeting 6: Diabetic Foot Problems

Place: NICE Offices
Level 1a
City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present: Damien Longson (Chair)
Rachael Hutchinson (RH)
Laurie King (LK)
Catherine Gooday (CG)
Sheila Burston (SBu)
Rachel Berrington (RB)
Sue Brown (SBr)
Issak Bhojani (IB)
Chizo Agwu (CA)
Susan Benbow (SBe)
Nicholas Foster (NF)
Stephen Hutchins (SH) (co-opted expert)
Fania Pagnamenta (FP) (co-opted expert)

Apologies: Gerry Rayman (GR)
Stella Vig (SV)

In attendance:

NICE Staff:
Stephanie Mills (SM)
Gabriel Rogers (GR)
Hugh McGuire (HM)
Vicky Gillis (VG)
Sarah Dunsdon (SD)
Michael Heath (MH)

Apologies:
Chris Gibbons (CG)

Observers:
Ania Wasielewska – NICE staff
1. DL welcomed all to the sixth diabetic foot guideline development group (GDG) meeting including 2 co-opted expert members, SH and FP. Apologies were received from GR and SA. DL stated that the objectives for the day were to look at two evidence reviews; the first related to debridement, wound dressings and off-loading, and the second covered clinical signs and symptoms of charcot arthropathy. CG, LK and RH declared work they were to be involved in but these declarations did not affect participation on the group. No further conflicts above what had already been made known to the NICE team were given. The group were asked to look at the minutes for GDG 5. They were agreed without amendment.

GR gave a brief update on the health economics (HE) and explained that a more detailed session on the progress of the HE model would be given at the next GDG meeting in June.

2. VG presented the evidence for review question 9. The GDG discussed the indirectness of the evidence presented and how generalisable it would be to UK clinical practice and settings. The committee also discussed the variation in terminology for types of casting and how this might be considered as the group interpreted the evidence base.

The GDG agreed, subsequent to minor wording tweaks, that the evidence statements presented were a representative summary of the evidence. The GDG then went on to make recommendations.

3. Following lunch, VG presented the evidence for review question 12. The GDG discussed the importance of defining types of charcot arthropathy and the need for swift action when charcot arthropathy is suspected. The GDG agreed the evidence statements based on some tweaks to the wording and bringing some of the statements together.

4. DL thanked the group for their hard work and also VG as this was her last meeting. SM let the group know the date, time and clinical areas to be covered at the next meeting.

**Date and venue of the next meeting**

Thurs 19\(^{th}\) June 2014 – NICE Offices, Manchester, 10am start